As an elusive covid-19 vaccine draws closer, big pharma is licking its lips at the monetary potential of what could be a virtually limitless ongoing global demand. But governments may use compulsory licensing regulation to tilt the scale towards affordability as the death toll escalates
Big pharma is racing to find covid-19 vaccines in the hope of profiting from a virtually limitless global demand, but governments are likely to step in to tilt the scale
